OncoMatch/Clinical Trials/NCT06551142
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Is NCT06551142 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for neoplasms.
Treatment: Ris-Rez · Cisplatin · Carboplatin · Atezolizumab · Pembrolizumab · Durvalumab · Cetuximab · Bevacizumab · Tarlatamab · Dostarlimab — The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anticancer therapy — advanced/metastatic
participants must have progressed on or become intolerant to all available SOC therapies
Cannot have received: B7-H3 targeted agent (orlotamab, enoblituzumab, I-Dxd)
Prior treatment with orlotamab, enoblituzumab, I-Dxd, or other B7-H3 targeted agents
Cannot have received: bone marrow transplant
any history of prior allogenic or autologous bone marrow transplant
Cannot have received: solid organ transplant
any history of prior ... solid organ transplant
Lab requirements
Cardiac function
QTc >450 msec or >480 msec for bundle branch block; evidence of current clinically significant arrhythmias or ECG abnormalities; risk factors for prolonged QTc or arrhythmia events; LVEF <50%; severe, uncontrolled or active CV disorders, serious or poorly controlled hypertension, clinically significant bleeding symptoms or serious arteriovenous thromboembolic events
Any of the following cardiac examination abnormality: QTc >450 msec or >480 msec for participants with bundle branch block; evidence of current clinically significant arrhythmias or ECG abnormalities (e.g., complete left bundle branch block, third-degree atrioventricular [AV] block, second-degree AV block, PR interval >250 msec); risk factors of prolonged QTc or arrhythmia events, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old or any concomitant medications that prolong the QT interval; LVEF <50%. Has severe, uncontrolled or active CV disorders, serious or poorly controlled hypertension, clinically significant bleeding symptoms or serious arteriovenous thromboembolic events
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Stanford, California
- GSK Investigational Site · Denver, Colorado
- GSK Investigational Site · New Haven, Connecticut
- GSK Investigational Site · Fort Wayne, Indiana
- GSK Investigational Site · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06551142 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7-H3 targeted agent, bone marrow transplant, solid organ transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify